MTOR and breast cancer: These observations were in line with the findings of previous studies that reported that PKM2 can enhance chemosensitivity to cisplatin through interacting with the mTOR pathway in cervical cancer, and GLS1 downregulation could re-sensitize the Taxol-resistant breast cancer cells to Taxol [17, 26].